ADMA vs. SMMT, GMAB, VTRS, ITCI, MRNA, RDY, CTLT, SRPT, PCVX, and QGEN
Should you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
ADMA Biologics vs.
Summit Therapeutics (NASDAQ:SMMT) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.
In the previous week, ADMA Biologics had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 12 mentions for ADMA Biologics and 10 mentions for Summit Therapeutics. ADMA Biologics' average media sentiment score of 0.95 beat Summit Therapeutics' score of 0.63 indicating that ADMA Biologics is being referred to more favorably in the news media.
ADMA Biologics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
Summit Therapeutics has a beta of -0.87, meaning that its share price is 187% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.
ADMA Biologics has a net margin of 17.80% compared to Summit Therapeutics' net margin of 0.00%. ADMA Biologics' return on equity of 53.20% beat Summit Therapeutics' return on equity.
Summit Therapeutics presently has a consensus price target of $33.57, suggesting a potential upside of 36.19%. ADMA Biologics has a consensus price target of $21.25, suggesting a potential upside of 28.17%. Given Summit Therapeutics' higher probable upside, research analysts plainly believe Summit Therapeutics is more favorable than ADMA Biologics.
4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 88.3% of Summit Therapeutics shares are owned by insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
ADMA Biologics received 110 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 72.08% of users gave ADMA Biologics an outperform vote while only 58.38% of users gave Summit Therapeutics an outperform vote.
Summary
ADMA Biologics beats Summit Therapeutics on 15 of the 19 factors compared between the two stocks.
Get ADMA Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADMA Biologics Competitors List
Related Companies and Tools
This page (NASDAQ:ADMA) was last updated on 1/24/2025 by MarketBeat.com Staff
